Osteopore Limited
OSX.ASXHealth Care
Production of 3D printed bioresorbable implants that are used conjunction with surgical procedures to assist with the natural stages of bone replacement.
Market Data
$0.006
-0.1%$3.8M
-100000.0x
$-0.020
0.00%
-0.6%
Latest Earnings
Appendix 4E Preliminary Final Report
27 February 2026
Osteopore Limited delivered record revenue of $3.06M (+11% YoY), demonstrating continued traction in regenerative medicine markets, but net losses widened to $3.72M (+11% YoY) due to higher product development, laboratory, and compliance expenses. The company maintains going concern viability supported by a $20M convertible note facility from Advance Opportunities Fund, though it faces a net asset deficiency of $1.73M and significant operational cash burn of $2.54M in 2025. Key points: Record annual revenue of $3.06M, up 11% YoY, reflecting stronger market traction and effective execution of market engagement strategies; Strong gross margin of 77.5% demonstrates healthy product economics despite expansion in cost of sales; Access to $20M convertible note facility from Advance Opportunities Fund provides substantial liquidity runway and going concern support
Recent Announcements
Becoming a substantial holder
ADVANCE OPPORTUNITIES FUND I became a substantial holder (8.47%).
Ceasing to be a substantial holder
Advance Opportunities Fund ceased to be a substantial holder.
Becoming a substantial holder
SUN JINGSI became a substantial holder (9.76%).
Becoming a substantial holder
ADVANCE OPPORTUNITIES FUND became a substantial holder (15.61%).
Ceasing to be a substantial holder
Advance Opportunities Fund I ceased to be a substantial holder.
Appendix 4E Preliminary Final Report
Osteopore Limited delivered record revenue of $3.06M (+11% YoY), demonstrating continued traction in regenerative medicine markets, but net losses widened to $3.72M (+11% YoY) due to higher product development, laboratory, and compliance expenses. The company maintains going concern viability supported by a $20M convertible note facility from Advance Opportunities Fund, though it faces a net asset deficiency of $1.73M and significant operational cash burn of $2.54M in 2025. Key points: Record annual revenue of $3.06M, up 11% YoY, reflecting stronger market traction and effective execution of market engagement strategies; Strong gross margin of 77.5% demonstrates healthy product economics despite expansion in cost of sales; Access to $20M convertible note facility from Advance Opportunities Fund provides substantial liquidity runway and going concern support
Get real-time alerts for OSX
Receive AI-powered earnings summaries and instant notifications when Osteopore Limited releases results.
Register Free